Title:
PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASE
Document Type and Number:
WIPO Patent Application WO/2019/209065
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition comprising ibrutinib as an effective ingredient for preventing or treating degenerative brain disease. Ibrutinib according to the present invention inhibits the activity of microglias or astrocytes to suppress the damage of activated microglias or activated astrocytes on neurons, exhibits the excellent effect of restraining the lipopolysaccharide (LPS)-induced migration of microglias, has the activity of reducing amyloid plaques and inhibiting the phosphorylation of tau proteins, and enhances memory and learning capability and thus can be used as a therapeutic agent for prevention or treatment of degenerative brain disease.
Inventors:
HOE HYANG SOOK (KR)
KIM JEOUNG YEON (KR)
NAM HYE YEON (KR)
LEE JU YOUNG (KR)
NAM YOUNG PYO (KR)
KANG RI JIN (KR)
LEE HYUN JU (KR)
KIM JEOUNG YEON (KR)
NAM HYE YEON (KR)
LEE JU YOUNG (KR)
NAM YOUNG PYO (KR)
KANG RI JIN (KR)
LEE HYUN JU (KR)
Application Number:
PCT/KR2019/005063
Publication Date:
October 31, 2019
Filing Date:
April 26, 2019
Export Citation:
Assignee:
DAEGU GYEONGBUK INST SCIENCE & TECH (KR)
International Classes:
A61K31/519; A61P25/00; A61P25/16; A61P25/28
Domestic Patent References:
| WO2017212420A1 | 2017-12-14 |
Foreign References:
| KR20150032340A | 2015-03-25 | |||
| US20170119760A1 | 2017-05-04 |
Other References:
ITO, M: "Bruton' s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury", NATURE COMMUNICATIONS, vol. 6, no. 7360, 10 June 2015 (2015-06-10), pages 1 - 11, XP055649272
WEI, L.: "Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes", ONCOTARGET, vol. 7, no. 43, 24 August 2016 (2016-08-24) - 25 October 2016 (2016-10-25), pages 69961 - 69975, XP055649279
SCHAPIRA, A.H., CURR. OPIN. NEUROL., vol. 9, no. 4, 1996, pages 260 - 264
WEI, L.: "Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes", ONCOTARGET, vol. 7, no. 43, 24 August 2016 (2016-08-24) - 25 October 2016 (2016-10-25), pages 69961 - 69975, XP055649279
SCHAPIRA, A.H., CURR. OPIN. NEUROL., vol. 9, no. 4, 1996, pages 260 - 264
Attorney, Agent or Firm:
NAM & NAM (KR)
Download PDF: